Results 141 to 150 of about 1,765 (165)

Genetic differences between Japan and other countries in cyp51A polymorphisms of Aspergillus fumigatus

Mycoses, 2021
AbstractBackgroundMutations in cyp51A gene are known as main mechanisms of azole resistance in Aspergillus fumigatus, whereas azole‐susceptible strains also carry cyp51A mutations (polymorphisms). The polymorphisms found in Europe mainly consist of two combinations of mutations, that is combinations of five single‐nucleotide polymorphisms (SNPs) of ...
Hidetaka Majima, Teppei Arai, Yoko Kusuya, Hiroki Takahashi, Akira Watanabe, Yasunari Miyazaki, Katsuhiko Kamei   +6 more
openaire   +2 more sources

Interrogation of related clinical pan-azole-resistant Aspergillus fumigatus strains: G138C, Y431C, and G434C single nucleotide polymorphisms in cyp51A, upregulation of cyp51A, and integration and activation of transposon Atf1 in the cyp51A promoter.

Antimicrobial agents and chemotherapy, 2011
Multiple Aspergillus fumigatus isolates from a patient with two aspergillomas complicating chronic pulmonary aspergillosis were pan-azole resistant. Microsatellite typing was identical for all isolates despite major phenotypic and some growth rate differences. Three different cyp51A mutations were found (G138C, Y431C, and G434C), of which the first two
Albarrag, Ahmed M., Anderson, Michael, Howard, Susan, Robson, Geoffrey, Warn, Peter, Sanglard, Dominique, Denning, David; id_orcid 0000-0001-5626-2251   +6 more
openaire   +2 more sources

Azole-resistant Aspergillus fumigatus with TR34/L98H mutations in the cyp51A gene in Iran

Journal de Mycologie Médicale, 2015
Introduction Triazole antifungal drugs such as itraconazole, posaconazole and voriconazole are the mainstay of therapy in the management and prophylaxis of aspergillosis. However, in recent years, triazole-resistant clinical isolates of Aspergillus fumigatus have emerged in Europe (the Netherlands, Denmark, Spain, UK, Belgium, Germany and France) and ...
Bita Mousavi, Hamid Badali
openaire   +1 more source

In vitro efficacy of the combination of voriconazole and anidulafungin against voriconazole-resistant cyp51A mutants of Aspergillus fumigatus

Diagnostic Microbiology and Infectious Disease, 2012
We selected voriconazole-resistant (VCZ-R) Aspergillus fumigatus in the laboratory, characterized the cyp51A gene for possible mutations and evaluated the in vitro activities of voriconazole and anidulafungin alone and in combination against VCZ-R isolates of A.
Suganthini, Krishnan-Natesan, Wenjuan, Wu, Pranatharthi H, Chandrasekar   +2 more
openaire   +2 more sources

Multi-azole resistant Aspergillus fumigatus harboring Cyp51A TR46/Y121F/T289A isolated in Japan

Journal of Infection and Chemotherapy, 2016
Multi-azole resistant Aspergillus fumigatus carrying TR46/Y121F/T289A was isolated from a patient in Japan in Dec 2013. This strain grouped into the same clade of the ones which were clinically isolated in France and Germany. A. fumigatus harboring this mutation could be rapidly diffused outside the Eurasian continent.
Daisuke, Hagiwara, Hiroki, Takahashi, Masanori, Fujimoto, Mai, Sugahara, Yoshiki, Misawa, Tohru, Gonoi, Satoru, Itoyama, Akira, Watanabe, Katsuhiko, Kamei   +8 more
openaire   +2 more sources

In vitro–in vivo correlation of voriconazole resistance due to G448S mutation (cyp51A gene) in Aspergillus fumigatus

Diagnostic Microbiology and Infectious Disease, 2012
Invasive pulmonary aspergillosis continues to be associated with a high mortality despite timely and appropriate therapy. Although host immunity plays a major role in poor clinical response, antifungal drug resistance cannot be ignored. Our studies were aimed 1) to study the mechanism of drug resistance in voriconazole strains of Aspergillus fumigatus,
S, Krishnan Natesan, Wenjuan, Wu, J L, Cutright, P H, Chandrasekar   +3 more
openaire   +2 more sources

Genomic perspective of triazole resistance in clinical and environmental Aspergillus fumigatus isolates without cyp51A mutations

Fungal Genetics and Biology, 2019
Aspergillus fumigatus is the most common etiologic agent of primarily all clinical manifestations of aspergillosis. A steady increase in the number of azole resistant A. fumigatus (ARAF) isolates from environment and clinical samples leading to therapeutic failures in clinical settings have alarmed the mycologists and clinicians worldwide.
Cheshta, Sharma, Shijulal, Nelson-Sathi, Ashutosh, Singh, M, Radhakrishna Pillai, Anuradha, Chowdhary   +4 more
openaire   +2 more sources

Detection of in vitro triazole resistance of Aspergillus fumigatus in clinical isolates sequencing cyp51A

2014
Aspergillosis due to Aspergillus fumigatus (A. fum.) is a common and life-threatening infection in immunocompromised patients. A. fum. is increasingly reported to be resistant to azoles essentially in prophylaxis and/or therapy of aspergillosis. Resistance is often associated with alterations in[for full text, please go to the a.m. URL]
Braun, A, Seibold, M, Tintelnot, K
openaire   +2 more sources

Cyp51A Dysfunction Leads to Higher Susceptibility to Azoles Including Fluconazole in Aspergillus fumigatus

Mycoses
ABSTRACTBackgroundAzoles target Cyp51A and Cyp51B in Aspergillus fumigatus. Mutations in cyp51A are known as the primary mechanisms of azole resistance. However, not all of them cause azole resistance. Among them, mutations related to improved susceptibility have not been reported so far.
Hidetaka Majima, Teppei Arai, Naoto Maruguchi, Katsuhiko Kamei, Akira Watanabe   +4 more
openaire   +2 more sources

A.fumigatus CYP51A Mutations in Lung Transplant Recipients

The Journal of Heart and Lung Transplantation, 2017
F. Cheema, L. McTaggart, L.G. Singer, D. Kumar, A. Humar, C. Rotstein, S. Keshavjee, J. Kus, T. Mazzulli, S. Husain   +9 more
openaire   +1 more source